Methods and compositions for in vivo clearance of pathogens
OwnerElliot R. Ramberg, Martin J. Lopezinventors
Life of this patent
Estimating the term…
Abstract
The present invention provides methods and compositions using biological factors, such as complement components, and manipulation of cells of erythroblastic lineage and myeloid lineage to facilitate clearance of pathologic targets from the blood stream of a patient in specific phagocytic compartment.
Claims33
A method for elimination of pathological agents from the blood of a patient comprising administering to said patient at least one sensitized erythrocyte having a molecule pair antibody complex that is capable of binding a pathological agent at a site other than the CR1 receptor, and eliminating said pathological agent from said patient's blood independent of the CR1 exchange reaction.
A method for blood-borne pathogen clearance in a patient in vivo comprising:
- a) administering to a patient an effective amount of a molecule pair, wherein said molecule pair is prepared using humanized or non-humanized antibodies;
- b) allowing said molecule pair to bind to a specific immunogenic site on at least one erythrocyte surface different to CR1 thereby forming a sensitized erythrocyte molecule pair;
- and
- c) allowing said sensitized erythrocyte molecule pair to bind to a specific pathological target in said patient's blood to any site on said erythrocyte other than the CR1 resulting in an erythrocyte-molecule pair-pathological target, and clearing said erythrocyte-molecule pair-pathological target from said patient's blood.
A method for blood-borne pathogen clearance in a patient in vivo comprising:
- a) sensitizing at least one erythrocyte with a molecule pair ex vivo;
- b) administering an effective amount of said sensitized erythrocyte molecule pair to said patient;
- and
- c) allowing said sensitized erythrocyte molecule pair to bind to a specific pathological agent resulting in an erythrocyte-molecule pair-pathological agent, and clearing said erythrocyte-molecule pair-pathological agent from said patient's blood.
A method for blood-borne pathogen clearance in a patient in vivo comprising:
- a) preparing at least one erythrocyte ghost having senescence markers;
- b) sensitizing at least one of said erythrocyte ghosts with at least one molecule pair ex vivo;
- c) administering an effective amount of said sensitized erythrocyte ghost molecule pair to a patient;
- and
- d) allowing said sensitized erythrocyte ghost molecule pair to bind to a specific pathological agent present in said patient's blood resulting in an erythrocyte ghost-molecule pair-pathological agent, and clearing said erythrocyte ghost-molecule pair-pathological agent through the privileged apoptotic or senescent cell natural clearance system of said patient's body.
A composition comprising an erythrocyte and a molecule pair antibody complex wherein said erythrocyte is capable of being bound to at least one of said molecule pair antibody complex at a site that is other than the CR1 receptor, and wherein said molecule pair antibody complex is capable of binding a pathological agent.
A composition comprising an erythrocyte ghost and a molecule pair antibody complex wherein said erythrocyte ghost is capable of being bound to at least one of said molecule pair antibody complex at a site that is other than the CR1 receptor, and wherein said molecule pair antibody complex is capable of binding a pathological agent.
Dependencies are inferred from the claim text.